nach oben

Medical Microbiology and Immunology

Erschienen in:

01.08.2013 | Original Investigation

Molecular and serological investigations of the Influenza A(H1N1) 2009 pandemic virus in Turkey

verfasst von: Meral Akcay Ciblak, Mustafa Hasoksuz, Melis Kanturvardar, Serkan Asar, Selim Badur

Erschienen in: Medical Microbiology and Immunology | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Intense research has been conducted on influenza A(H1N1)pdm09 virus to determine the virulence markers. Limited information on characteristics of pandemic virus has become available in Turkey since the pandemic. In this first report from Turkey, we investigated the molecular markers that have been associated with increased virulence and oseltamivir resistance. We also conducted serological studies in people after infection, vaccination, exposure, and no-exposure controls to determine the level of protection against the pandemic H1N1 influenza virus. Thirteen rRT-PCR positive samples were analyzed for presence of mutations that have been associated with host range, virulence, and antiviral resistance: substitution D222G in the HA, E627K in the PB2, and H275Y in the neuraminidase (NA). In addition, 135 serum samples from vaccinated, recovered, asymptomatic contacts, and control individuals were tested using hemagglutination inhibition (HI) assay. D222G was detected in nasal samples from two severe cases. No specified mutations in the PB2 and NA were identified. Additional substitutions, I216V, V321I, E374K, S203T in HA, V655I in PB2, and I163V in NA, were detected. HI testing from vaccinated individuals, recovered patients, asymptomatic contacts, and control individuals showed that 97.9, 99.7, 88.2, and 44.2 % had HI titers ≥40, respectively. Molecular markers promoting influenza A(H1N1)pdm09 to become a pandemic virus are still under investigation. Serological results confirm that younger, un-exposed individuals are at increased risk of pandemic virus infections. Influenza A(H1N1)pdm09 viruses are still in circulation around the globe. Therefore, these viruses need to be monitored closely for development of new markers including antiviral resistance mutations.

World Health Organization (2009) World now at the start of 2009 influenza pandemic http://who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_20090611/en/index.html. Accessed 15 October 2012

World Health Organization (2009) Clinical features severe cases of pandemic influenza http://www.who.int/csr/disease/swineflu/notes/h1n1_clinical_features_20091016/en/index.html. Accessed 15 October 2012

Ciblak MA, Albayrak N, Odabas Y, BasakAltas A, Kanturvardar M, Hasoksuz M et al (2009) Cases of influenza A(H1N1)v reported in Turkey, May–July 2009. Eur Surveill 14(32):19304

Chowell G, Bertozzi SM, Colchero MA, Lopez-Gatell H, Alpuche-Aranda C, Hernandez M et al (2009) Severe respiratory disease concurrent with the circulation of H1N1 influenza. N Engl J Med 361:674–679CrossRefPubMed

Echevarría-Zuno S, Mejía-Aranguré JM, Mar-Obeso AJ, Grajales-Muñiz C, Robles-Pérez E, González-León M et al (2009) Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis. Lancet 374:2072–2079CrossRefPubMed

Pebody RG, McLean E, Zhao H, Cleary P, Bracebridge S, Foster K et al (2010) Pandemic Influenza A (H1N1) 2009 and mortality in the United Kingdom: risk factors for death, April 2009 to March 2010. Eur Surveill 15(20):19571

World Health Organization. Public health significance of virus mutation detected in Norway (November 2009) http://www.who.int/csr/disease/swineflu/notes/briefing_20091120/en/ Accessed 18 October 2012

Kilander A, Rykkvin R, Dudman SG, Hungnes O (2009) Observed association between the HA1 mutation D222G in the 2009 pandemic influenza A(H1N1) virus and severe clinical outcome, Norway 2009–2010. Eur Surveill 15(9):19498

Chutinimitkul S, Herfst S, Steel J, Lowen AC, Ye J, van Riel D et al (2010) Virulence-associated substitution D222G in the hemagglutinin of 2009 pandemic influenza A (H1N1) virus affects receptor binding. J Virol 84:11802–11813CrossRefPubMed

10.

Liu Y, Childs RA, Matrosovich T, Wharton S, Palma AS, Chai W et al (2010) Altered receptor specificity and cell tropism of D222G hemagglutinin mutants isolated from fatal cases of pandemic A(H1N1) 2009 influenza virus. J Virol 84:12069–12074CrossRefPubMed

11.

Belser JA, Jayaraman A, Raman R, Pappas C, Zeng H, Cox NJ et al (2011) Effect of D222G mutation in the hemagglutinin protein on receptor binding, pathogenesis and transmissibility of the 2009 pandemic H1N1 influenza virus. PLoS One 6(9):e25091CrossRefPubMed

12.

Miller RR, MacLean AR, Gunson RN, Carman WF (2010) Occurrence of haemagglutinin mutation D222G in pandemic influenza A (H1N1) infected patients in the West of Scotland, United Kingdom, 2009–10. Eur Surveill 5(16):19546

13.

Melidou A, Gioula G, Exindari M, Chatzidimitriou D, Diza E, Malisiovas N (2010) Molecular and phylogenetic analysis of the haemagglutinin gene of pandemic influenza H1N1 2009 viruses associated with severe and fatal infections. Virus Res 151:192–199CrossRefPubMed

14.

Puzelli S, Facchini M, De Marco MA, Palmieri A, Spagnolo D, Boros S et al (2010) Molecular surveillance of pandemic influenza A(H1N1) viruses circulating in Italy from May 2009 to February 2010: association between haemagglutinin mutations and clinical outcome. Eur Surveill 15(43):19696

15.

Wang B, Dwyer DE, Soedjono M, Shi H, Matlho K, Ratnamohan M et al (2011) Evidence of the circulation of pandemic influenza (H1N1) 2009 with D222D/G/N/S hemagglutinin polymorphisms during the first wave of the 2009 influenza pandemic. J Clin Virol 52:304–306CrossRefPubMed

16.

Almond JW (1977) A single gene determines the host range of influenza virus. Nature 270:617–618CrossRefPubMed

17.

Subbarao EK, London W, Murphy BR (1993) A single amino acid in the PB2 gene of influenza A virus is a determinant of host range. J Virol 67:1761–1764PubMed

18.

Shinya K, Hamm S, Hatta M, Ito H, Ito T, Kawaoka Y (2004) PB2 amino acid at position 627 affects replicative efficiency, but not cell tropism, of Hong Kong H5N1 influenza A viruses in mice. Virology 320:258–266CrossRefPubMed

19.

Chen GW, Chang SC, Mok CK, Lo YL, Kung YN, Huang JH et al (2006) Genomic signatures of human versus avian influenza A viruses. Emerg Infect Dis 12:1353–1360CrossRefPubMed

20.

Mehle A, Doudna JA (2009) Adaptive strategies of the influenza virus polymerase for replication in humans. Proc Natl Acad Sci U S A 106:21312–21316CrossRefPubMed

21.

Centers for Disease Control and Prevention (2009) Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. Morb Mortal Wkly Rep 58:521–524

22.

World Health Organization (2009) CDC protocol of realtime RTPCR for swine influenza A(H1N1). http://www.who.int/csr/resources/publications/swineflu/CDCrealtimeRTPCRprotocol_20090428.pdf. Accessed September 2012

23.

Strengell M, Ikonen N, Ziegler T, Julkunen I (2011) Minor changes in the hemagglutinin of influenza A(H1N1)2009 virus alter its antigenic properties. PLoS One 6(10):e25848CrossRefPubMed

24.

Barr IG, Cui L, Komadina N, Lee RT, Lin RT, Deng Y et al (2010) A new pandemic influenza A (H1N1) genetic variant predominated in the winter 2010 influenza season in Australia New Zealand and Singapore. Eur Surveill 15(42):19692

25.

Jayaraman A, Pappas C, Raman R, Belser JA, Viswanathan K, Shriver Z et al (2011) A single base-pair change in 2009 H1N1 hemagglutinin increases human receptor affinity and leads to efficient airborne viral transmission in ferrets. PLoS One 6(3):e17616CrossRefPubMed

26.

Capua I, Kajaste-Rudnitski A, Bertoli E, Vicenzi E (2009) Pandemic vaccine preparedness–have we left something behind? PLoS Pathog 5(6):e1000482CrossRefPubMed

27.

Wood JM (1998) Standardization of inactivated influenza vaccines. In: Nicholson KG, Webster RG, Hay AJ (eds) Textbook of influenza. Blackwell, Oxford, p 333

Titel: Molecular and serological investigations of the Influenza A(H1N1) 2009 pandemic virus in Turkey
verfasst von: Meral Akcay Ciblak
Mustafa Hasoksuz
Melis Kanturvardar
Serkan Asar
Selim Badur
Publikationsdatum: 01.08.2013
Verlag: Springer Berlin Heidelberg
Erschienen in: Medical Microbiology and Immunology / Ausgabe 4/2013
Print ISSN: 0300-8584
Elektronische ISSN: 1432-1831
DOI: https://doi.org/10.1007/s00430-013-0291-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Molecular and serological investigations of the Influenza A(H1N1) 2009 pandemic virus in Turkey

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2013

Progress in VZV vaccination? Some concerns

Subneutralizing antibodies to enterovirus 71 induce antibody-dependent enhancement of infection in newborn mice

Lower nasopharyngeal epithelial cell repair and diminished innate inflammation responses contribute to the onset of acute otitis media in otitis-prone children

Herpes simplex virus 1 DNA polymerase processivity factor UL42 inhibits TNF-α-induced NF-κB activation by interacting with p65/RelA and p50/NF-κB1

Molecular epidemiology and genetic diversity of human rhinovirus affecting hospitalized children in Rome

TLR4, IL10RA, and NOD2 mutation in paediatric Crohn’s disease patients: an association with Mycobacterium avium subspecies paratuberculosis and TLR4 and IL10RA expression

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin